CONMED
Makes surgical devices for orthopedic and minimally invasive general procedures.
Something off on this page? Send us feedback.
Profile
Sells orthopedic and general-surgery devices, with product families spanning sports medicine, powered instruments, AirSeal insufflation, smoke evacuation, electrosurgery, and patient monitoring. Revenue is mostly recurring single-use products, with a meaningful international base and an active exit from gastroenterology.
Develops, manufactures, and sells surgical devices used in orthopedic surgery and general surgery. The portfolio includes sports-medicine implants and suture anchors, BioBrace soft-tissue repair, Hall powered instruments, AirSeal insufflation and access, Buffalo Filter smoke evacuation, electrosurgery, laparoscopic instruments, and patient-monitoring products.
Operates as one global segment while reporting the business through Orthopedic Surgery and General Surgery product lines. Sales are meaningfully international, and the model relies heavily on recurring single-use products alongside capital equipment.
Executes through procedure-specific product platforms and acquisitions that added Linvatec, SurgiQuest, Buffalo Filter, In2Bones, and Biorez. Current portfolio shape is affected by the exit from gastroenterology product lines, regulated medical-device markets, hospital purchasing cycles, and competition from larger medtech companies.
Company facts
Categories
Key statistics
Year to date +23.5% · Average volume (30d) 474.9K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Jul 13, 2026 | Wells Fargo | Target | $39 | ||
| Jul 8, 2026 | BMO Capital | Initiate | Market Perform | $36 | |
| Jun 29, 2026 | Bank of America Securities | Downgrade | Underperform | ||
| Jun 29, 2026 | B of A Securities | Downgrade | Neutral | Underperform | |
| Mar 17, 2026 | Piper Sandler | Downgrade | Overweight | Neutral |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026Q2 FY26 | $1.11 | $1.38 | +24.3% | $337.6M | $343.5M | +1.7% | +8.72% |
| Apr 29, 2026Q1 FY26 | $0.82 | $0.89 | +8.5% | $310.6M | $317.0M | +2.1% | +1.95% |
| Jan 28, 2026Q4 FY25 | $1.32 | $1.43 | +8.3% | $366.9M | $373.2M | +1.7% | −3.57% |
| Nov 5, 2025Q3 FY25 | $1.05 | $1.08 | +2.9% | $366.9M | $337.9M | −7.9% | −0.52% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $319.4M | $343.0M | $338.6M | $373.5M | $317.0M | $343.5M | |
| Gross profit | $167.9M | $180.5M | $158.0M | $213.3M | $183.4M | $197.5M | |
| Operating income | $11.5M | $41.7M | $19.4M | $66.9M | $25.4M | $36.4M | |
| Net income | $6.0M | $21.4M | $2.9M | $16.7M | $13.8M | $23.1M | |
| Diluted EPS | $0.19 | $0.69 | $0.09 | $0.54 | $0.45 | $0.77 | |
| Gross margin | 52.6% | 52.6% | 46.7% | 57.1% | 57.9% | 57.5% | |
| Operating margin | 3.6% | 12.2% | 5.7% | 17.9% | 8.0% | 10.6% |
Fiscal years (4-quarter sums)FY21 $1.01B · FY22 $1.05B · FY23 $1.24B · FY24 $1.31B · FY25 $1.37B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $37.3M · Total debt $834.2M · Total assets $2.30B · Shareholders' equity $1.04B
Dividends
Raised for 13 straight years. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Sep 15, 2025 | Sep 15 | Oct 3 | $0.20 | |
| Jun 13, 2025 | Jun 13 | Jul 3 | $0.20 | |
| Mar 14, 2025 | Mar 14 | Apr 4 | $0.20 | |
| Dec 20, 2024 | Dec 20 | Jan 3 | $0.20 | |
| Sep 16, 2024 | Sep 16 | Oct 4 | $0.20 | |
| Jun 14, 2024 | Jun 14 | Jul 5 | $0.20 | |
| Mar 14, 2024 | Mar 15 | Apr 5 | $0.20 | |
| Dec 15, 2023 | Dec 18 | Jan 5 | $0.20 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 29.95M · Float 29.82M · 99.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 4.82M | 16.10% | 13F | Aug 7, 2026 |
| Earnest Partners LLC | 2.51M | 8.36% | 13F | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 2.19M | 7.31% | 13F | Aug 13, 2026 |
| Fuller & Thaler Asset Management, Inc. | 1.58M | 5.27% | 13F | Aug 12, 2026 |
| State Street Corp | 1.42M | 4.73% | 13F | Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Nov 21, 2025 | Richard Glaze | officer: Chief Information Officer | −257 | $41.21 |
| Nov 6, 2025 | Todd W. Garner | officer: Executive Vice President & CFO | −3,500 | $43.00 |
| Sep 12, 2025 | Charles Farkas | director | −2,000 | $53.52 |
Peers
- Stryker
Broad overlap in orthopedics, instruments, and endoscopy
- Johnson & Johnson
DePuy Synthes and Ethicon span orthopedics and surgery
- Medtronic
Medical-surgical scale in endoscopy, energy, and monitoring
- Smith & Nephew (ADR)
Sports medicine and orthopaedics peer with direct soft-tissue overlap
- Zimmer Biomet
Orthopedic reconstruction, S.E.T., and foot-and-ankle overlap
- Globus Medical
Musculoskeletal technology overlap in trauma and enabling systems
- Treace Medical Concepts
Focused foot-and-ankle competitor in bunion and midfoot repair
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CONMED | $49.53 | −1.06% | $1.50B | 27.0 | 11.2 | 1.1 | +0.3% |
| Stryker | $334.18 | +1.06% | $126.77B | 34.3 | 20.6 | 4.9 | +9.4% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Smith & Nephew (ADR) | $28.72 | −0.93% | $12.17B | 19.2 | — | 1.9 | +3.7% |
| Zimmer Biomet | $100.91 | −0.00% | $19.52B | 24.6 | 11.5 | 2.3 | +4.8% |
| Globus Medical | $85.02 | +2.47% | $11.19B | 21.3 | 16.2 | 3.6 | +5.9% |
| Treace Medical Concepts | $4.65 | −0.21% | $301.7M | — | — | 1.5 | −4.2% |
| Median | 24.5 | 16.2 | 3.2 | +5.9% |